Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Kidney cancer: Does hypothyroidism predict clinical outcome?

Nature Reviews Urology volume 8, pages 10–11 (2011)Cite this article

Subjects

Hypothyroidism is a commonly reported side effect of treatment with sunitinib and sorafenib. A recent study has correlated development of subclinical hypothyroidism with clinical outcome, notably response rate and overall survival, in patients with metastatic renal cell carcinoma who are being treated with these drugs.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Schmidinger, M. et al. Hypothyroidism in patients with renal cell carcinoma: blessing or curse? Cancer doi:10.1002/cncr.25422.

  2. Rini, B. I. et al. Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J. Natl Cancer Inst. 99, 81–83 (2007).

    Article  CAS  Google Scholar 

  3. Tamaskar, I. et al. Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib. Ann. Oncol. 19, 265–268 (2008).

    Article  CAS  Google Scholar 

  4. Miyake, H. et al. Abnormalities of thyroid function in Japanese patients with metastatic RCC treated with sorafenib: a prospective evaluation. Urol. Oncol. 28, 515–519 (2010).

    Article  CAS  Google Scholar 

  5. Motzer, R. J., Bacik, J., Murphy, B. A., Russo, P. & Mazumdar, M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J. Clin. Oncol. 20, 289–296 (2002).

    Article  CAS  Google Scholar 

  6. Heng, D. Y. et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J. Clin. Oncol. 27, 5794–5799 (2009).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Institute, 9500 Euclid Avenue, Cleveland, 44195, OH, USA

    Brian Rini

Authors
  1. Brian Rini
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

The author declares an association with Pfizer, for whom he acts as a consultant and receives research funding.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rini, B. Kidney cancer: Does hypothyroidism predict clinical outcome?. Nat Rev Urol 8, 10–11 (2011). https://doi.org/10.1038/nrurol.2010.191

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrurol.2010.191

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing